Avecho Biotechnology Expands Trials and Manufacturing
Company Announcements

Avecho Biotechnology Expands Trials and Manufacturing

Avecho Biotechnology Limited (AU:AVE) has released an update.

Avecho Biotechnology Limited has made significant strides in the third quarter of 2024, continuing its Phase III clinical trials for an innovative CBD soft-gel capsule aimed at treating insomnia while also ramping up manufacturing for its US partner, Ashland. The company invested heavily in research and development and maintained a solid cash reserve as of September. These developments highlight Avecho’s commitment to expanding its product offerings and strengthening its financial position.

For further insights into AU:AVE stock, check out TipRanks’ Stock Analysis page.

Related Articles
TipRanks Australian Auto-Generated NewsdeskAvecho Biotech Reports Decreased Revenue and Rising Losses
TipRanks Australian Auto-Generated NewsdeskAvecho Biotech Advances Insomnia Treatment Trial
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App